nach oben

Current Rheumatology Reports

Erschienen in:

01.06.2010

Update on the Assessment of Children with Juvenile Idiopathic Inflammatory Myopathy

verfasst von: Adam M. Huber

Erschienen in: Current Rheumatology Reports | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

The availability of validated measurement tools to assess children with juvenile idiopathic inflammatory myopathies is critical to clinical care and to ongoing research into new therapeutic modalities and approaches. Recent work has led to the development of tools for assessment of muscle strength and physical function, skin disease, global disease activity and damage, extramuscular disease, and quality of life. Ongoing work is attempting to integrate these assessments into core sets and definitions of improvement and flare. Future work will refine these assessments and definitions and—where there are multiple choices—determine which tools constitute an optimal assessment.

Mendez EP, Lipton R, Ramsey-Goldman R, et al.; NIAMS Juvenile DM Registry Physician Referral Group: US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003, 49:300–305.CrossRefPubMed

Medical Research Council: Aids to the Investigation of Peripheral Nerve Injuries. Memorandum No. 7, edn 2. London: Her Majesty’s Stationery Office; 1943.

Kendall FP, McCreary EK, Provance PG: Muscles: Testing and Function, edn 4. Baltimore, MD: Williams & Wilkins; 1993.

Jain M, Smith M, Cintas H, et al.: Intra-rater and inter-rater reliability of the 10-point manual muscle test (MMT) of strength in children with juvenile idiopathic inflammatory myopathies (JIIM). Phys Occup Ther Pediatr 2006, 26:5–17.PubMed

• Rider LG, Koziol D, Giannini EH, et al.: Validation of manual muscle testing and a subset or eight muscles (MMT8) for adult and juvenile idiopathic inflammatory myopathy. Arthritis Care Res 2010, 62(4):465–472. This important study documents that the MMT8 has measurement characteristics that are similar to the full 26-muscle version.

Singh G, Athreya BH, Fries JF, Goldsmith DP: Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994, 37:1761–1769.CrossRefPubMed

Feldman BM, Ayling-Campos A, Luy L, et al.: Measuring disability in juvenile dermatomyositis: validity of the Childhood Health Assessment Questionnaire. J Rheumatol 1995, 22:326–331.PubMed

Huber AM, Hicks JE, Lachenbruch PA, et al.; Juvenile Dermatomyositis Disease Activity Collaborative Study Group: Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic inflammatory myopathies. J Rheumatol 2001, 28:1106–1111.PubMed

Lovell DJ, Lindsley CB, Rennebohm RM, et al.: Development of disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis Rheum 1999, 42:2213–2219.CrossRefPubMed

10.

Huber AM, Feldman BM, Rennebohm RM, et al. Validation and clinical significance of the Childhood Myositis Assessment Scale (CMAS) for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2004, 50:1595–1603.CrossRefPubMed

11.

Rennebohm RM, Jones K, Huber AM, et al.; Juvenile Dermatomyositis Disease Activity Collaborative Study Group: Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale (CMAS). Arthritis Rheum 2004, 51:365–370.CrossRefPubMed

12.

Ruperto N, Ravelli A, Murray KJ, et al.; Pediatric Rheumatology International Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG): Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology 2003, 42:1452–1459.CrossRefPubMed

13.

Miller FW, Rider LG, Chung YL, et al.; International Myositis Outcome Assessment Collaborative Study Group: Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathy. Rheumatology (Oxford) 2001, 40:1262–1273.CrossRef

14.

Hundley JL, Carroll CL, Lang W, et al.: Cutaneous symptoms of dermatomyositis significantly impact patients’ quality of life. J Am Acad Dermatol 2006, 54:217–220.CrossRefPubMed

15.

Bode RK, Klein-Gitelman MS, Miller ML, et al.: Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Care Res 2003, 49:7–15.CrossRef

16.

•• Ruperto N, Ravelli A, Pistorio A, et al.; Paediatric Rheumatology International Trials Organisation (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG): The provisional Pediatric Rheumatology International Trials Organization/American College of Rheumatology/European League Against Rheumatism disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 2008, 59:4–13. This study provides valuable validation of several measures used in the assessment of children with myositis, based on the PRINTO core set measures.CrossRefPubMed

17.

Isenberg D, Allen E, Farewell V, et al.; International Myositis and Clinical Studies Group (IMACS). International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004, 43:49–54.CrossRef

18.

Huber AM, Dugan EM, Lachenbruch PA, et al.; Juvenile Dermatomyositis Disease Activity Collaborative Study Group: The Cutaneous Assessment Tool (CAT): development and reliability in juvenile idiopathic inflammatory myopathy. Rheumatology (Oxford) 2007, 46:1606–1611.CrossRef

19.

• Huber AM, Dugan EM, Lachenbruch PA, et al.; Juvenile Dermatomyositis Disease Activity Collaborative Study Group: Preliminary validation and clinical meaning of the Cutaneous Assessment Tool (CAT) in juvenile dermatomyositis. Arthritis Rheum 2008, 59:214–221. This article provides validation for the only comprehensive skin assessment tool that is currently available.CrossRefPubMed

20.

Huber AM, Lachenbruch PA, Dugan EM, et al.; Juvenile Dermatomyositis Disease Activity Collaborative Study Group: Alternative scoring of the Cutaneous Assessment Tool (CAT) in juvenile dermatomyositis: results using an abbreviated format. Arthritis Rheum 2008, 59:352–356.CrossRefPubMed

21.

Carroll CL, Lang W, Snively B, et al.: Development and validation of the Dermatomyositis Skin Severity Index. Br J Dermatol 2008, 158:345–350.PubMed

22.

Klein RQ, Bangert CA, Costner M, et al.: Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol 2008, 159:887–894.CrossRefPubMed

23.

Yassaee M, Fiorentino D, Okawa J, et al.: Modification of the Cutaneous Dermatomyositis Disease Area and Severity Index, an outcome instrument. Br J Dermatol 2009 Oct 26 (Epub ahead of print).

24.

Rider LG, Feldman BM, Perez MD, et al.: Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. I. Physician, parent and patient global assessments. Arthritis Rheum 1997, 40:1976–1983.CrossRefPubMed

25.

• Rider LG, Lachenbruch PA, Monroe JB, et al.; IMACS Group: Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum 2009, 60:3425–3435. This work validates the first (and currently only) damage assessment for children with myositis. It also documents and compares the extent of damage seen in both pediatric and adult myositis populations.CrossRefPubMed

26.

Landgraf J, Abetz L, Ware J: The CHQ User’s Manual. Boston, MA: The Health Institute; 1996.

27.

• Apaz MT, Saad-Magalhães C, Pistorio A, et al.; Paediatric Rheumatology International Trials Organisation: Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study. Arthritis Rheum 2009, 61:509–517. This is the only project to date to specifically study and validate a measure of health-related quality of life in a cohort of children with myositis.CrossRefPubMed

28.

Oddis CV, Rider LG, Reed AM, et al.; International Myositis Assessment and Clinical Studies Group: International consensus guidelines for the trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 2005, 52:2607–2615.CrossRefPubMed

29.

Rider LG, Giannini EH, Brunner HI, et al.; International Myositis Assessment and Clinical Studies Group: International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004, 50:2281–2290.CrossRefPubMed

30.

Bohan A, Peter JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292:344–347.PubMedCrossRef

31.

Rider LG, Schiffenbauer AS, Zito M, et al.; Juvenile Dermatomyositis Disease Activity Collaboration Study Group: Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies. Clin Chem 2002, 48:1681–1688.PubMed

32.

O’Connor KA, Abbott KA, Sabin B, et al.: MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. Clin Immunol 2006, 120:319–325.CrossRefPubMed

33.

Bakay M, Wang Z, Melcon G, et al.: Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rb-MyoD pathways in muscle regeneration. Brain 2006, 129:996–1013.CrossRefPubMed

34.

Tezak Z, Hoffman EP, Lutz JL, et al.: Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol 2002, 168:4154–4163.PubMed

35.

Fall N, Bove KE, Stringer K, et al.: Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis. Arthritis Rheum 2005, 52:3175–3180.CrossRefPubMed

36.

Baechler EC, Bauer JW, Slattery CA, et al.: An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007, 13:59–68.CrossRefPubMed

37.

•• Feldman BM, Rider LG, Reed AM, Pachman LM: Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008, 371:2201–2212. This is an outstanding review of the current state of knowledge about the pathogenesis of juvenile myositis, written by four leaders in the field.CrossRefPubMed

38.

• Bilgic H, Ytterberg SR, Amin S, et al.: Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009, 60:3436–3446. This study documents the association between type I interferon-regulated genes and chemokines with disease activity and provides significant optimism that laboratory-based assessments of disease activity may be approaching development.CrossRefPubMed

39.

Chung YL, Rider LG, Bell JD, et al.; Juvenile Dermatomyositis Disease Activity Collaborative Study Group: Muscle metabolites, detected in urine by proton spectroscopy, correlate with disease damage in juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2005, 53:565–570.CrossRefPubMed

40.

Eisenstein DM, O’Gorman MR, Pachman LM: Correlations between change in disease activity and changes in peripheral blood lymphocyte subsets in patients with juvenile dermatomyositis. J Rheumatol 1997, 24:1830–1832.PubMed

41.

O’Gorman MR, Bianchi L, Zaas D, et al.: Decreased levels of CD54 (ICAM-1)-positive lymphocytes in the peripheral blood in untreated patients with active juvenile dermatomyositis. Clin Diagn Lab Immunol 2000, 7:693–697.PubMed

42.

McCann LJ, Juggins AD, Maillard SM, et al.; Juvenile Dermatomyositis Research Group: The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)—clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford) 2006, 45:1255–1260.CrossRef

43.

Brown VE, Pilkington CA, Feldman BM, Davidson JE; Network for Juvenile Dermatomyositis, Paediatric Rheumatology European Society (PReS): An international consensus survey on the diagnostic criteria for juvenile dermatomyositis. Rheumatology (Oxford) 2006, 45:990–993.CrossRef

44.

• Wedderburn LR, Varsani H, Li CK, et al.: International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum 2007, 57:1192–1201. This work describes an attempt to standardize and validate the assessment of muscle biopsy specimens in juvenile myositis.CrossRefPubMed

45.

Miles L, Bove KE, Lovell D, et al.: Predictability of the clinical course of juvenile dermatomyositis based on initial muscle biopsy: a retrospective study of 72 patients. Arthritis Rheum 2007, 57:1183–1191.CrossRefPubMed

46.

• Gardner Medwin JM, Irwin G, Johnson K: MRI in juvenile idiopathic arthritis and juvenile dermatomyositis. Ann N Y Acad Sci 2009, 1154:52–83. This is an excellent review of the use of MRI in the assessment of children with myositis.CrossRefPubMed

47.

Maillard SM, Jones R, Owens C, et al.: Quantitative assessment of MRI T2 relaxation time in thigh muscles in juvenile dermatomyositis. Rheumatology (Oxford) 2004, 43:603–608.CrossRef

48.

Tzaribachev N, Well C, Schedel J, Horger M: Whole-body MRI: a helpful diagnostic tool for juvenile dermatomyositis case report and review of the literature. Rheumatol Int 2009, 29:1511–1514.CrossRefPubMed

49.

Summers RM, Brune AM, Choyke PL, et al.: Juvenile idiopathic inflammatory myopathy: exercise-induced changes in muscle at short inversion time inversion-recovery imaging. Radiology 1998, 209:191–196.PubMed

50.

Punaro L, Stichweh D, Powell M, et al.: Aspiration: hidden risk for patients with juvenile dermatomyositis [abstract]. Clin Exp Rheumatol 2004, 22(Suppl):S104.

51.

McCann LJ, Garay SM, Ryan MM, et al.: Oropharyngeal dysphagia in juvenile dermatomyositis (JDM):an evaluation of videofluoroscopy swallow study (VFSS) changes in relation to clinical symptoms and objective muscle scores. Rheumatology 2007, 46:1363–1366.CrossRefPubMed

Titel: Update on the Assessment of Children with Juvenile Idiopathic Inflammatory Myopathy
verfasst von: Adam M. Huber
Publikationsdatum: 01.06.2010
Verlag: Current Science Inc.
Erschienen in: Current Rheumatology Reports / Ausgabe 3/2010
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-010-0103-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

Theories of the Pathogenesis of Inclusion Body Myositis

Mechanical Factors and Bone Health: Effects of Weightlessness and Neurologic Injury

Dermatomyositis and Type 1 Interferons

Bone Changes and Fracture Risk in Individuals Infected With HIV

Drug-related Myopathies of Which the Clinician Should Be Aware